Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables (2021 - 2025)

BridgeBio Pharma's Receivables history spans 4 years, with the latest figure at $139.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 2853.07% year-over-year to $139.4 million; the TTM value through Dec 2025 reached $139.4 million, up 2853.07%, while the annual FY2025 figure was $139.4 million, 2853.07% up from the prior year.
  • Receivables for Q4 2025 was $139.4 million at BridgeBio Pharma, up from $116.5 million in the prior quarter.
  • Across five years, Receivables topped out at $139.4 million in Q4 2025 and bottomed at $2.4 million in Q4 2023.
  • The 4-year median for Receivables is $76.9 million (2025), against an average of $66.5 million.
  • The largest annual shift saw Receivables soared 100.85% in 2024 before it surged 2853.07% in 2025.
  • A 4-year view of Receivables shows it stood at $10.2 million in 2021, then crashed by 76.89% to $2.4 million in 2023, then skyrocketed by 100.85% to $4.7 million in 2024, then soared by 2853.07% to $139.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Receivables are $139.4 million (Q4 2025), $116.5 million (Q3 2025), and $76.9 million (Q2 2025).